FilingSEC EDGAR8-K
Coya Therapeutics completes enrollment of 100th patient in Phase 2/3 ALSTARS trial.
· SEC accepted
StagePhase 2/3
Filing content
The company reached 100 patients enrolled in its Phase 2/3 ALSTARS trial for COYA 302 and expects to report topline data in early Q2 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…